To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
19 Current news of GlobalData
rss
Fake Avastin Reignites “Track-and-Trace” Debate, but the Clock is Ticking
15-06-2012
The US Food and Drug Administration (FDA) announced in February that counterfeit vials of Roche/Genentech’s cancer drug Avastin were sold to a number of medical practices across the country. While the exact sources of the phony drug remain a mystery, authorities traced the fake batch through ...
Expert Insight: Patent Cliff Revenues Fertilize Generics Companies
05-06-2012
When we think about the patent cliff, an image along the lines of a massive waterfall, with companies’ revenues in free fall comes to mind. What we usually forget to consider, though, is that the waterfall is nourishing a fertile, green valley below. For while big pharmaceutical companies are ...
Pharmaceutical Research into Spinal Cord Injuries Will Stretch into Next Decade
21-05-2012
Drugs under development to treat those affected by acute spinal cord injuries are not expected to emerge within the current decade, leaving the market largely open to new entrants, according to a new report issued by pharmaceuticals intelligence provider GlobalData.The new report, "Acute ...
Big Pharma and Biotech Increasingly Tackling Rare and Niche Diseases
15-05-2012
Rare and niche diseases are being increasingly spotlighted by pharmaceutical and biotechnology corporations in the hope of developing initial treatments or improving upon existing therapies for these conditions, according to a new report released by GlobalData.The new report, "Rare and Niche ...
To Improve Cancer Treatment, Look to the Sky
30-04-2012
Arguably, two of the most noteworthy advancements in medicine and technology in the last decade have been genomics research and cloud computing, according to GlobalData. These two advancements have been on separate pathways, each having little to do with the other - until now. Today, medical ...
Roche Steps Back from Illumina Acquisition
24-04-2012
F. Hoffman-La Roche dropped its bid to buy Illumina after Illumina’s shareholders made it clear at the company’s annual meeting that the terms were inadequate. Roche had made a $51 per share tender offer for San Diego-based Illumina, but allowed the offer to expire. GlobalData analyzed the ...
Dyeing to Paint the Alzheimer’s Brain
16-04-2012
Alzheimer’s disease (AD) is a neurodegenerative disease of the brain characterized by beta-amyloid plaques. Most patients are diagnosed late-stage in the disease or are misdiagnosed with another form of dementia. The three hallmark biomarkers for AD are neurofibrillary “tangles”, protein ...
Antidepressants Continue to Dominate the OCD Therapeutics Market
10-04-2012
Treatment options for obsessive compulsive disorder (OCD) are currently dominated by antidepressants, and this trend is expected to continue for the next seven to eight years, unless drugmakers step up their future research to develop new, more effective treatments, according to a new report ...
Shaking-up Gene Delivery in the Neurodegenerative Disease World
27-03-2012
FierceBiotech recently announced its list of “10 Top Next-Gen Biotech Platforms”. Among the list is San Diego-based Ceregene, which is developing a novel neurotrophic factor gene therapy delivery via adeno-associated virus vectors (AAV). According to FierceBiotech, Ceregene’s ...
Netmeeting
